VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

Shaney L Barratt, Victoria A Flower, John D Pauling, Ann B Millar

Research output: Contribution to journalReview articlepeer-review

79 Citations (SciVal)


Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.

Original languageEnglish
Article number1269
Pages (from-to)1-17
Number of pages17
JournalInternational Journal of Molecular Sciences
Issue number5
Publication statusPublished - 24 Apr 2018


  • Journal Article
  • Review
  • VEGF
  • Fibrosis
  • Interstitial lung disease
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Molecular Biology
  • Spectroscopy
  • Catalysis
  • Inorganic Chemistry
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry


Dive into the research topics of 'VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease'. Together they form a unique fingerprint.

Cite this